Effect of Sitagliptin on Postprandial Lipoprotein Metabolism
Information source: Ludwig-Maximilians - University of Munich
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus Type 2
Intervention: sitagliptin (Drug); glimepiride (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Ludwig-Maximilians - University of Munich Overall contact:
Klaus G Parhofer, MD, Phone: +49-89-7095, Ext: 3010, Email: klaus.parhofer@med.uni-muenchen.de
Summary
The goal of the study is to evaluate whether sitagliptin can affect postprandial lipoprotein
metabolism in type 2 diabetic patients.
Clinical Details
Study design: N/A
Primary outcome: AUC following standardized fat meal
Secondary outcome: other lipid parameters
Eligibility
Minimum age: 19 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- type 2 diabetes
- dietary therapy
Exclusion Criteria:
- lipid-lowering therapy
- anti-hyperglycemic drug therapy
Locations and Contacts
Klaus G Parhofer, MD, Phone: +49-89-7095, Ext: 3010, Email: klaus.parhofer@med.uni-muenchen.de
Medical Dept. 2, Grosshadern, University Munich, Munich 81377, Germany
Additional Information
Last updated: July 14, 2009
|
